false
ar,be,bn,zh-CN,zh-TW,en,fr,de,hi,it,ja,ko,pt,ru,es,sw,vi
Catalog
Emerging data in platinum resistance advanced ovar ...
Recording
Recording
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In this IGCS webinar, Dr. David O'Malley and Dr. Lainey Martin discuss emerging data on platinum-resistant advanced ovarian cancer. They emphasize the importance of early testing for biomarkers like folate receptor alpha and HRD, helping guide treatment decisions. The focus is on using therapies like Mirvotuximab soravtansine (MIRV) in patients with high folate receptor alpha expression, even in less than 75% cases. They discuss the efficacy, tolerability, and management of potential side effects, particularly eye toxicity. The discussion also highlights the use of maintenance therapy, including Bevacizumab, and the importance of global access to testing and treatments. This informative session underscores the need for personalized approaches to optimize patient care.
Keywords
IGCS webinar
Dr. David O'Malley
Dr. Lainey Martin
platinum-resistant advanced ovarian cancer
biomarkers
Mirvotuximab soravtansine
Contact
education@igcs.org
for assistance.
×